BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33681389)

  • 1. Related Pentacyclic Triterpenes Have Immunomodulatory Activity in Chronic Experimental Visceral Leishmaniasis.
    de Jesus JA; Laurenti MD; Antonangelo L; Faria CS; Lago JHG; Passero LFD
    J Immunol Res; 2021; 2021():6671287. PubMed ID: 33681389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileishmanial and immunomodulatory activities of lupeol, a triterpene compound isolated from Sterculia villosa.
    Das A; Jawed JJ; Das MC; Sandhu P; De UC; Dinda B; Akhter Y; Bhattacharjee S
    Int J Antimicrob Agents; 2017 Oct; 50(4):512-522. PubMed ID: 28669838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of ursolic acid in experimental visceral leishmaniasis.
    Jesus JA; Fragoso TN; Yamamoto ES; Laurenti MD; Silva MS; Ferreira AF; Lago JH; Santos-Gomes G; Passero LF
    Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):1-11. PubMed ID: 27984757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lupeol and amphotericin B mediate synergistic anti-leishmanial immunomodulatory effects in Leishmania donovani-infected BALB/c mice.
    Das A; Jawed JJ; Das MC; Parveen S; Ghosh C; Majumdar S; Saha B; Bhattacharjee S
    Cytokine; 2021 Jan; 137():155319. PubMed ID: 33002744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
    Charan Raja MR; Velappan AB; Chellappan D; Debnath J; Kar Mahapatra S
    Eur J Med Chem; 2017 Oct; 139():503-518. PubMed ID: 28826085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
    Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
    J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis.
    Bilbao-Ramos P; Serrano DR; Ruiz Saldaña HK; Torrado JJ; Bolás-Fernández F; Dea-Ayuela MA
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32204358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: A promising chemotype targeting visceral leishmaniasis.
    Chandrakar P; Gunaganti N; Parmar N; Kumar A; Singh SK; Rashid M; Wahajuddin M; Mitra K; Narender T; Kar S
    Eur J Med Chem; 2019 Nov; 182():111632. PubMed ID: 31499363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
    Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
    Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
    Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum.
    Lage PS; Chávez-Fumagalli MA; Mesquita JT; Mata LM; Fernandes SO; Cardoso VN; Soto M; Tavares CA; Leite JP; Tempone AG; Coelho EA
    Parasitol Res; 2015 Dec; 114(12):4625-35. PubMed ID: 26346453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
    Freitas CS; Santiago SS; Lage DP; Antinarelli LMR; Oliveira FM; Vale DL; Martins VT; Magalhaes LND; Bandeira RS; Ramos FF; Pereira IAG; de Jesus MM; Ludolf F; Tavares GSV; Costa AV; Ferreira RS; Coimbra ES; Teixeira RR; Coelho EAF
    Exp Parasitol; 2023 Aug; 251():108555. PubMed ID: 37247802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Potential of Quercetin-Loaded Nanoemulsion against Experimental Visceral Leishmaniasis:
    Das SS; Dubey AK; Verma PRP; Singh SK; Singh SK
    Mol Pharm; 2022 Sep; 19(9):3367-3384. PubMed ID: 35980291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A.
    Zheng ZW; Li J; Chen H; He JL; Chen QW; Zhang JH; Zhou Q; Chen DL; Chen JP
    Parasit Vectors; 2020 Feb; 13(1):94. PubMed ID: 32085719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
    Eberhardt E; Mondelaers A; Hendrickx S; Van den Kerkhof M; Maes L; Caljon G
    Parasitol Res; 2016 Oct; 115(10):4061-70. PubMed ID: 27412759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue Specific Dual RNA-Seq Defines Host-Parasite Interplay in Murine Visceral Leishmaniasis Caused by Leishmania donovani and Leishmania infantum.
    Forrester S; Goundry A; Dias BT; Leal-Calvo T; Moraes MO; Kaye PM; Mottram JC; Lima APCA
    Microbiol Spectr; 2022 Apr; 10(2):e0067922. PubMed ID: 35384718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.